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Abstract
Background: NT1014 is a novel biguanide and AMPK activator with a high affinity for the organic cation-specific
transporters, OCT1 and OCT3. We sought to determine the anti-tumorigenic effects of NT1014 in human ovarian
cancer cell lines as well as in a genetically engineered mouse model of high-grade serous ovarian cancer.
Methods: The effects of NT1014 and metformin on cell proliferation were assessed by MTT assay using the human
ovarian cancer cell lines, SKOV3 and IGROV1, as well as in primary cultures. In addition, the impact of NT1014 on
cell cycle progression, apoptosis, cellular stress, adhesion, invasion, glycolysis, and AMPK activation/mTOR pathway
inhibition was also explored. The effects of NT1014 treatment in vivo was evaluated using the K18 − gT121+/−; p53fl/
fl; Brca1fl/fl (KpB) mouse model of high-grade serous ovarian cancer.
Results: NT1014 significantly inhibited cell proliferation in both ovarian cancer cell lines as well as in primary
cultures. In addition, NT1014 activated AMPK, inhibited downstream targets of the mTOR pathway, induced G1 cell
cycle arrest/apoptosis/cellular stress, altered glycolysis, and reduced invasion/adhesion. Similar to its anti-
tumorigenic effects in vitro, NT1014 decreased ovarian cancer growth in the KpB mouse model of ovarian cancer.
NT1014 appeared to be more potent than metformin in both our in vitro and in vivo studies.
Conclusions: NT1014 inhibited ovarian cancer cell growth in vitro and in vivo, with greater efficacy than the
traditional biguanide, metformin. These results support further development of NT1014 as a useful therapeutic
approach for the treatment of ovarian cancer.
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Background
Ovarian cancer is a highly fatal disease that is estimated
to cause 14,240 deaths in 2016 in the USA alone [1, 2].
Despite advances in treatment, the 5-year overall
survival for ovarian cancer is approximately 40 %. While
80 % of patients will initially respond to cytoreductive
surgery and platinum-based combination chemotherapy,
the vast majority of women with advanced ovarian
cancer will ultimately develop a recurrence and chemo-
resistant disease. Thus, there is an urgent need to
develop novel therapies for this deadly disease [3, 4].
Obesity is associated with increased risk and worse
outcomes for ovarian cancer [5]. The Ovarian Cancer
Association Consortium reported that a high BMI, at all
stages of life, was associated with an increased risk of
developing ovarian cancer [6], while a large prospective
cohort study and two systematic reviews reported an
increased risk of mortality from ovarian cancer in obese
patients [7–9]. In addition to obesity, type II diabetes
appears to effect ovarian cancer survival. A recent study
following 642 cases of ovarian cancer over a 10-year
period found that diabetics with ovarian cancer had
significantly worse overall survival as compared to non--
diabetics, even after multivariable adjustment [10]. In
addition, our laboratory has shown that the metabolic
effects of obesity promote ovarian cancer progression
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and aggressiveness in a genetically engineered mouse
model of serous ovarian cancer [11].
The biguanide, metformin, is one of the most widely
prescribed treatments for type II diabetes. Epidemio-
logical studies suggest that metformin use for the
treatment of type II diabetes may reduce the risk of
developing ovarian cancer. This reduction in risk may be
due to inhibition of cellular proliferation via AMPK-
dependent or AMPK-independent pathways and/or by
reducing elevated systemic insulin levels [12–14]. Several
recent studies have reported that metformin has an
ability to inhibit cell proliferation, adhesion, migration,
and angiogenesis in ovarian cancer cell lines and mouse
models [15–18]. Our laboratory has found that metfor-
min inhibits cell proliferation in a dose-dependent
manner in ovarian cancer cell lines and reduces tumor
growth in a genetically engineered mouse model of
serous ovarian cancer fed with high-fat and low-fat diets
(submitted).
Metformin is transported into cells by organic cation
transporters (OCTs) 1, 2, and 3. These transporters are
expressed at varying levels in different organs including
the liver, muscle, ovary, and kidney [19, 20]. OCT1 and
OCT3 are highly expressed in epithelial ovarian cancer
and ovarian germ cell tumors, respectively [21, 22].
OCT2 is predominantly expressed in the kidney and is
responsible for metformin clearance in the urine.
Urinary excretion of metformin results in the short
half-life of metformin as well as the wide range of peak
to trough drug levels seen, particularly in patients with
impaired renal function [19, 23]. Recent studies have
shown that inhibition of OCT2 activity by the OCT2
inhibitor cimetidine in patients treated with cisplatin
resulted in a decreased cisplatin-induced nephrotoxicity
by restricting the accumulation of cisplatin in the kidney
[24–26]. Thus, development of novel biguanide agents,
designed to increase their affinity for OCT1 and OCT3
while minimizing their affinity for OCT2, may result in
more potent drugs with a longer plasma half-life than
metformin. Biguanides with this profile may have
profound effects on metabolic parameters as OCT1 is
highly expressed in the liver whereas OCT3 is expressed
in the skeletal muscle [19, 27, 28].
We have recently designed, synthesized, and screened
approximately 140 biguanides in an attempt to identify
compounds with a high affinity for OCT1 and OCT3 and
with a reduced activity at OCT2. The biguanide, NT1014,
has activity for OCT1 and 3 and reduced potency for
OCT2. Moreover, NT1014 at 20 % the dose of metformin
was demonstrated to result in activation of AMPK, inhib-
ition of hepatic glucose output in rat hepatocytes, reduced
rate of gastric emptying in mice, increased glucose
disposal, and glucose-stimulated glucagon-like peptide-
1(GLP1) release (data not shown). In the present study,
we investigated the potential of NT1014 as a therapeutic
agent for ovarian cancer by evaluating the anti-tumor
effects of NT1014 as compared to metformin in human
ovarian cancer cell lines and a genetically engineered
mouse model of serous ovarian cancer.
Methods
Cell culture and reagents
Ovarian cancer cell lines, IGROV-1 and SKOV3, were
used in these experiments. IGROV-1 cells were grown in
RPMI 1640 medium containing 10 % fetal bovine serum.
SKOV3 cells were grown in DMEM/F12 medium with
10 % fetal bovine serum. These two cell lines were
cultured with 1 % penicillin-streptomycin at 37 °C under a
humidified atmosphere containing 5 % CO2. NT1014 was
provided by NovaTarg Therapeutics (Cary, NC). Metfor-
min, 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetra-
zolium bromide (MTT), and RNase A were purchased
from Sigma (St. Louis, MO). All antibodies were obtained
from Cell Signaling (Danvers, MA). The L-lactate assay
kit was bought from Eton Bioscience (San Diego, CA).
2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-
D-glucose (2-NBDG), caspase 3 assay kit, and ATP assay
kit were bought from AAT Bioquest (Sunnyvale, CA).
Annexin V FITC kit was purchased from BioVision
(Mountain View, CA). Enhanced chemiluminescence
Western blotting detection reagents were purchased from
Amersham (Arlington Heights, IL). All other chemicals
were purchased from Sigma (St. Louis, MO).
Cell proliferation assay
The MTT assay was employed to measure cell prolifera-
tion. Briefly, the IGROV-1 and SKOV3 cells were seeded
in 96-well plates at a density of 4000 cells/well and
allowed to attach overnight. The culture medium was
replaced with fresh medium containing NT1014 or met-
formin (from 0.01 to 3000 μM), and cells were incubated
for 72 h. After drug treatment, MTT (5 mg/ml) was
added to the 96-well plates at 5 μl/well for an additional
incubation time of 1 h. The MTT reaction was termi-
nated through the replacement of the media by 100 μl
DMSO. The results were determined by measuring the
absorbance at 575 nm with a micro-plate reader (Tecan,
Morrisville, NC). The effect of NT1014 and metformin
was calculated as a relative percentage of control cell
growth obtained from DMSO (0.1 %)-treated cells grown
in the same 96-well plates. Each experiment was
performed in triplicate and repeated three times to
assess for consistency of results.
Cell cycle analysis
The effect of NT1014 on cell cycle progression was
measured using Cellometer (Nexcelom, Lawrence, MA).
Briefly, the IGROV1 and SKOV3 cells were plated at
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2.5 × 105 cells/well in six-well plates and incubated
overnight. Plates were then treated with NT1014 (from
0.1 to 1000 μM) for 24 h. The cells were harvested by
trypsin digestion and washed with phosphate-buffered
saline (PBS), before being re-suspended and fixed in
90 % pre-chilled methanol and stored at −20 °C over-
night. The cells were treated with 50 μl RNase A
solution (250 μg/ml, 10 mM EDTA) for 30 min at 37 °C
and then stained with 50 μl of staining solution (contain-
ing 2 mg/ml propidium iodide (Hayward, MA), 0.1 mg/
ml azide, and 0.05 % Triton X-100). The final mixture
was incubated for 15 min in the dark before being
analyzed by Cellometer. The results were analyzed using
FCS4 express software (Molecular Devices, Sunnyvale,
CA). The experiments were performed in triplicate and
repeated three times for assessment of consistency.
Annexin V assay
The percentage of cells actively undergoing apoptosis
was assessed with the annexin V FITC assay kit. The
IGROV-1and SKOV3 cells (2 × 105 cells/well) were
treated with NT1014 (from 0.1 to 1000 μM) for 24 h.
The cells were then collected, washed with PBS, re-
suspended in 100 μl of annexin V and propidium iodide
(PI) dual-stain solution (0.1 μg of annexin V FITC and
1 μg of PI), and allowed to incubate for 15 min in the
dark. The samples were then analyzed via Cellometer.
The results were analyzed by FCS4 express software. All
experiments were performed in triplicate and repeated
three times to assess for consistency of response.
Cleaved caspase 3 assay
Cleaved caspase 3 was detected using the cleaved
caspase 3 activity assay kit. The IGROV-1 and SKOV3
cells were seeded at 6000 cells/well in a 96-well plate for
24 h and then treated with media containing different
concentrations of NT1014 (1–1000 μM) for 4 h. We
then added 100 μl of caspase 3 assay loading buffer into
each well, mixed gently, and incubated the cells for
60 min at room temperature. The fluorescence intensity
was measured at an excitation wavelength of 350 nm
and an emission wavelength of 450 nm using a plate
reader (Tecan). All experiments were performed at least
twice to assess for consistency of response.
ROS assay
The alteration of total production of reactive oxygen
species caused by NT1014 was measured using a
DCFH-DA fluorescent dye. The IGROV-1 and SKOV3
cells (1.0 × 104 cells/well) were seeded in black 96-well
plates. After 24 h, the cells were treated with NT1014
(0.1 to 1000 μM) for 4 h to induce reactive oxygen
species (ROS) generation. After the cells were incubated
with DCFH-DA (20 μM) for 30 min, the fluorescence
was monitored at an excitation wavelength of 485 nm
and an emission wavelength of 530 nm using a plate
reader (Tecan). All experiments were performed at least
twice to assess for consistency of response.
Adhesion assay
Each well in a 96-well plate was coated with 100 μl
laminin-1 (10 μg/ml) and incubated at 37 °C for 1 h.
This fluid was then aspirated, and 200 μl blocking buffer
was added to each well for 45–60 min at 37 °C. The
wells were then washed with PBS, and each plate was
allowed to chill on ice. Next, 2.5 × 103 cells were added
with PBS to each well, followed by varying concentra-
tions of NT1014. Each plate was then allowed to
incubate at 37 °C for 2 h. After this period, the medium
was aspirated, and cells were fixed by adding 100 μl of
5 % glutaraldehyde and incubating for 30 min at room
temperature. Adherent cells were then washed with PBS
and stained with 100 μl of 0.1 % crystal violet for
30 min. The cells were then washed repeatedly with
water, and 100 μl of 10 % acetic acid was added to each
well. After 5 min of shaking, the absorbance was
measured at 570 nm using a micro-plate reader (Tecan).
Each experiment was repeated at least twice for
consistency of response.
Invasion assay
Ninety-six-well HTS transwells (Corning Life Sciences,
Durham, NC) coated with 0.5–1X BME (Trevigen,
Gaithersburg, MD) were used to examine the effect of
NT1014 on the ability of ovarian cancer cells to invade.
The IGROV-1 and SKOV3 cells (50,000 cells/well) were
starved for 12 h and then added in the upper chambers
of the wells in 50 μl FBS-free medium. The lower
chambers were filled with 150 μl medium with various
concentrations of NT1014. The plate was then incubated
for 4 h at 37 °C to allow invasion into the lower cham-
ber. After washing the upper and lower chambers with
PBS, 100 μl calcein AM solution was added into the
lower chamber and incubated at 37 °C for 30–60 min.
The lower chamber plate was measured by the plate
reader (Tecan) using an excitation wavelength of
485 nm and an emission wavelength of 520 nm. Each
experiment was performed at least twice for consistency
of response.
ATP assay
ATP production was detected by using the luminometric
ATP assay kit (AAT bioquest, Sunnyvale, CA), following
the manufacturer’s instructions. Each well of a 96-well
white plate was seeded with 5 × 103 cells and incubated
overnight. Wells were then treated with different doses
of NT1014 for 24 h. Next, 100 μl of ATP assay solution
was added into each well, gently mixed, and allowed to
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incubate for 20 min at room temperature. The lumines-
cence intensity was measured using the luminometer
mode on a plate reader (Tecan). Finally, the measured
ATP levels were normalized based on viable cell counts
as measured by MTT assay. The experiments were
performed in triplicate and repeated three times for
consistency of response.
Lactate production assay
The L-Lactate Assay Kit was used to measure L-lactate
production in the medium. Briefly, after we treated cells
with different concentrations of NT1014 for 24 h, 10 μl
of the culture medium was transferred into a new
96-well plate, and 40 μl of distilled water was added to
each well. Each well was mixed with another 50 μl of
lactate assay solution, incubated for 30 min at 37 °C
without CO2. The lactate level was measured at
wavelength of 490 nm using a plate reader (Tecan). The
experiments were performed in triplicate and repeated
twice to assure consistency.
Glucose uptake assay
The IGROV-1 and SKOV3 cells were seeded into
96-well black plates at 4000 cells/well overnight and
then treated with NT1014 under varying concentrations
of glucose for 24 h. After treatment, cells were cultured
with 2-NBDG (100 μg/ml) in glucose-free medium for
15 min. The 2-NBDG uptake reaction was stopped by
removing the medium and washing the cells twice with
200 μl HBSS (Life Technologies Corporation, Grand
Island, NY). Fluorescence intensity was measured at an
excitation wavelength of 485 nm and an emission
wavelength of 530 nm using a plate reader (Tecan).
Relative glucose was assayed compared with untreated
control. Data were normalized based on the viable cell
counts measured by MTT assay. All the experiments
were performed in triplicate and repeated three times.
Western blot analysis
The IGROV-1 and SKOV3 cells were collected at the end
of drug treatment, and total protein was extracted using
RIPA buffer (Boston Bioproducts, Ashland, MA) supple-
mented with protease/phosphatase inhibitor. Equal
amounts (30 μg) of total protein were loaded and
separated by 10–12 % SDS-PAGE and then transferred to
a PVDF membrane. The blot was subsequently blocked in
5 % non-fat milk and incubated with a 1:1000 dilution of
primary antibodies at 4 °C overnight. The membranes
were then washed and incubated with the appropriate
secondary antibodies for 1 h at room temperature before
development. The bands were developed and quantified
using an Alpha Innotech Imaging System (San Leandro,
CA, USA). After developing, the membranes were
stripped or washed and re-probed using antibodies against
total AMPK or pan-S6 and α-tubulin (for all proteins),
respectively. The intensity of bands was measured and
normalized to α-tubulin. Each experiment was repeated at
least twice for consistency of results.
KpB mouse model
The K18 − gT121+/−; p53fl/fl; Brca1fl/fl (KpB) mouse
model has been described previously in detail [11, 29].
All mice were handled according to protocols approved
by UNC-CH Institutional Animal Care and Use Com-
mittee (IACUC). The KpB mice were injected with
recombinant adenovirus Ad5-CMV-Cre (AdCre, Trans-
fer Vector Core, University of Iowa) into the left ovarian
bursa cavity at 6–8 weeks age. The mice were randomly
divided into three groups with one group receiving
NT1014 oral garage (dose of 75 mg/kg for 4 weeks)
daily, one group receiving metformin in oral gavage
(75 mg/kg for 4 weeks), and the other group receiving
placebo once the ovarian tumor size had reached 0.1 ×
0.1 cm in diameter by palpation. Tumor size was
monitored twice-weekly using palpation until tumors
had grown to a size amenable to caliper measurement.
All mice were euthanized after 4 weeks of NT1014 and
placebo treatment. Tumor volume was calculated using
the following: (width2 × length)/2. Tumor tissues and
blood samples were collected for immunohistochemical
(IHC) staining and VEGF assay.
Immunohistochemical analysis
Five micrometer paraffin sections were prepared from
the KpB mice tumors and were used for IHC analysis.
Staining procedures were performed at the IHC Mice
Core Facility at UNC. The following primary antibodies
were used: Ki-67, phosphorylated-AKT, phosphorylated-
AMPK, phosphorylated-S6, and MMP9. Further process-
ing was carried out using ABC-Staining Kits (Vector
Labs, Burlingame, CA) and hematoxylin. IHC slides
were scanned by Aperio and scored by ImageScope
software (Vista, CA).
Statistical analysis
Data is expressed as mean ± SEM. Data was compared
using two-tailed Student’s t test, and p < 0.05 was consid-
ered significant. Data was analyzed using Prism (Graph-
Pad Software, La Jolla, USA).
Results
NT1014 has high affinity for OCT1 and OCT3
NT1014 was designed, synthesized, and identified in
targeted screening using the ethidium bromide uptake
assay in HEK293 cells (Fig. 1a). The cells were stably
transfected with hOCT1, 2, or 3, and the uptake of
metformin and NT1014 was measured in each cell type
and in neo (control) cells at 37 °C for 2.5 min (Fig. 1b).
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NT1014 had a higher affinity for OCT1 and OCT3 and
a reduced activity for OCT2 compared to metformin
(Fig. 1c). In addition, MTT assays indicated that NT1014
treatment resulted in a 16-fold increase in growth inhib-
ition (IC50 value) in HEK293 cells stably transfected
with OCT1 compared to HEK293 control cells and a
5-fold increase in growth inhibition (IC50) in HEK293
cells stably transfected with OCT3 (Fig. 1d). These
results when compared to metformin demonstrate the
improved affinity of NT1014 for OCT1 and OCT3 and
the reduced affinity for OCT2.
NT1014 inhibits cell proliferation in ovarian cancer cells
The IGROV-1 and SKOV3 ovarian cancer cell lines were
found to express OCT1, OCT2, and OCT3, by Western
blotting analysis (Fig. 2a). Using the MTT cytotoxicity
assay, the IGROV-1 and SKOV3 ovarian cancer cell lines
were found to have a progressive decrease in cell viability
with increasing concentrations of NT1014 for 72 h
(Fig. 2b). The IC50 values for the IGROV-1 and SKOV3
cells were 200 and 450 μM, respectively, suggesting that
IGROV-1 cells are more sensitive to NT1014 than the
SKOV3 cells. Subsequently, we compared the effect of
NT1014 and metformin on cell proliferation in both cell
types. We observed that NT1014 and metformin at low
doses (0.01 to 10 μM) produced the same inhibitory
effects on cell proliferation. However, NT1014 at high
doses was found to increase the growth inhibition in both
cells compared to metformin at the same dosages, which
the IC50 values were lower for NT1014 than metformin
(Fig. 2c, d). To further determine growth inhibitory
function of NT1014, we examined the effect of NT1014
and metformin in primary cultures of human ovarian
cancers. Cell proliferation in the nine primary cell cultures
was assessed by MTT assay after exposure to NT1014 or
metformin for 72 h. All nine primary cultures responded
to NT1014 or metformin treatment. Lower IC50 values
were found for NT1014 as compared to metformin in 6/9
of the primary cultures (Fig. 2e). These results suggest that
NT1014 may have improved potency over metformin in
inhibition of cell proliferation.
To investigate the effects of NT1014 on expression of
OCT1, OCT2, and OCT3/4 in the IGROV-1 and SKOV3
cells, we treated both cell lines with 500 μM NT1014 in a
time course fashion. NT1014 decreased OCT1 and
OCT3/4 expression in both cell lines, with the greatest
effects seen in both cell lines after 24 h of exposure to
NT1014. NT1014 did not affect OCT2 expression in the
IGROV-1 cells and slightly increased OCT2 expression
after 6 h of treatment in the SKOV3 cells. Next, we treated
the cells with different doses of NT1014 for 24 h and
evaluated the effect of different concentrations of NT1014
on the expression of the OCTs. The level of OCT1 and
OCT3/4 protein expression in both cells was decreased in
a dose-dependent manner (Fig. 2f). To ascertain whether
the effect of NT1014 was mediated by AMPK pathway,
we characterized the effect of NT1014 on downstream
targets of the AMPK/mTOR/S6 pathway. NT1014 in-
creased phosphorylation of AMPK and decreased
phosphorylation of S6 expression in both cell lines after
24 h of treatment (Fig. 2g).
NT1014 induced cell cycle G1 arrest and cellular
apoptosis
The effects of NT1014 on cell cycle progression and
apoptosis were evaluated in the IGROV-1 and SKOV3
cell lines. The cells were treated with NT1014 at varying
concentrations for 24 h, and Cellometer was used to
analyze the cell cycle. NT1014 treatment resulted in G0/
G1 cell cycle arrest and reduced S phase in a dose-
Fig. 1 NT1014 has high affinity for OCT1 and OCT3. Molecular structure of NT1014 (a). HEK293 cells were stably transfected with hOCT1, 2, and 3
(b). Blue color represents nuclei. Affinity for OCT1, OCT2, and OCT3 after treatment of NT1014 or metformin (c). MTT assay were used to assess the
growth inhibition by NT1014 and metformin in HEK293 cells transfected with OCT1 and OCT3 (d). *p < 0.05 and **p < 0.01
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dependent manner in both cell lines (Fig. 3a, b). While
the percent of cells in G1 phase increased from 68.2 to
87.7 %, the S phase cell population decreased from 9.6
to 5.5 % with increasing concentrations of NT1014 in
the IGROV-1 cells. NT1014 also increased the percent
of cells in G1 phase by 9.7 % with concordant reduction
of S phase cells by 2.2 % at the dose of 1000 mM in the
SKOV3 cell line.
To further characterize NT1014’s effects on cell cycle
arrest, cell cycle-related proteins were analyzed in
NT1014-treated IGROV-1 and SKOV3 cells. Western
blotting results showed that NT1014 down-regulated
cyclin D1 and CDK4 and CDK6 protein expression and
upregulated cell cycle inhibitor p21 and p27 expression
in both cell lines (Fig. 3c). To confirm whether the
growth inhibition of ovarian cancer cells was related to
apoptosis, the apoptotic effect of NT1014 was evaluated
in the IGROV-1 and SKOV3 cells by annexin V FITC
stain analysis. Annexin V FITC detects the phospholipid
phosphatidylserine (PS) translocation from the inner
(cytoplasmic) leaflet of the cell membrane to the exter-
nal surface in early apoptotic cells. The apoptotic cell
population significantly increased in a dose-dependent
manner in both cell lines after 24 h of exposure to
NT1014 (Fig. 3d). We next determined whether the
mitochondrial apoptosis pathway which leads to caspase
activation and induces cell death was involved in
NT1014-induced apoptosis in the ovarian cancer cell
lines. We treated both cell lines with increasing concen-
trations of NT1014 for 4 h, and the activity of cleaved
caspase 3 was detected by ELISA assay. A dose-
dependent increase in the activity of cleaved caspase 3
was found in both cell lines in response to NT1014
(Fig. 3e). Furthermore, NT1014 produced a decrease in
protein expression of BCL-XL and MCL-1 in a dose-
dependent manner after treatment with NT1014 for
24 h in both cell lines (Fig. 3f ). These results suggest
that NT1014 inhibits cell proliferation through the
induction of mitochondrial apoptosis and cell cycle G1
arrest in ovarian cancer cells.
NT1014 induces cellular stress in ovarian cancer cells
ROS have been implicated in the cellular response to
stress and are involved in the mediation of apoptosis via
Fig. 2 NT1014 inhibited cell proliferation in ovarian cancer cells. The expression of OCT1, OCT2, and OCT3/4 in the IGROV-1 and SKOV3 cell lines
was detected by Western blotting (a). The IGROV-1 and SKOV3 cells were incubated with NT1014 (from 0.01 to 3000 μM) in 96-well plates for
72 h, and cell proliferation was assessed by MTT assay (b). MTT assay also used to compare the growth inhibition of metformin and NT1014 in
both cells (c, d). NT1014 inhibited cell growth in nine primary cultures of ovarian cancer (e). IGROV-1 and SKOV3 cells were treated with NT1014
in a time course fashion or treated with different doses for 24 h, and expression of OCT1, OCT2 and OCT3/4 was determined by Western blotting.
Equal loading was confirmed with an anti-β-actin antibody (f). NT1014 increased the expression of phos-AMPK and decreased phos-S6 expression
in both cells after 24 h of treatment (g). *p < 0.05 and **p < 0.01
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mitochondrial DNA damage [20]. Metformin has been
shown to induce cell stress in different types of cancer
[30]. To investigate the involvement of oxidative stress
in the anti-proliferative effect of NT1014, intracellular
ROS levels were examined using the ROS fluorescence
indicator DCF-DA. NT1014 and metformin (0.1–
1000 μM) significantly increased ROS production in a
dose-dependent manner in the IGROV-1 and SKOV3
cells after 4 h of treatment (Fig. 4a, b). In addition,
NT1014 significantly increased ROS levels in both cells
compared to metformin at dose of 1000 μM. We next
examined the alternations of endoplasmic reticulum
(ER) stress-related markers after 24 h treatment of
NT1014 in both cell lines. Our Western blotting results
showed that NT1014 significantly induced the protein
expression of Bip, PERK, and calnexin in a dose-
dependent manner (Fig. 4c). These results indicate that
an increase in ROS production and ER stress might also
be involved in the anti-tumorigenic effects of NT1014 in
ovarian cancer cells.
NT1014 inhibits cell adhesion and invasion in ovarian
cancer cells
In vitro adhesion and invasion assays were performed to
evaluate the effect of NT1014 on metastatic activity. Cell
adhesion assays were performed using laminin-1 as an
adhesion substrate. NT1014 (100 and 1000 μM)
treatment of the IGROV-1 and SKOV3 cells for 2 h
showed a significant reduction in adhesion to laminin-1
compared with untreated control (17–24 % in IGROV-1
cells and 10–18 % in SKOV3 cells, p < 0.05) (Fig. 5a).
Both cell lines were again treated with NT1014 at differ-
ent concentrations for 24 h to determine the effect of
NT1014 on cell invasion. NT1014 (100 and 1000 μM)
significantly decreased cell invasion activity after 24 h of
treatment (15–28 % in IGROV-1 cells and 11–23 % in
SKOV3 cells, p < 0.05), as determined by the transwell
invasion assay (Fig. 5b).
Cell adhesion and invasion are mediated by a variety
of membrane proteins as well as modulation of cytoskel-
etal assembly. To further analyze the effect of NT1014
on cell motility and migration of ovarian cancer cells,
the levels of expression of E-cadherin, β-catenin, Slug,
and vimentin were analyzed by Western blot. After 24 h
of treatment, NT1014 increased expression of E-
cadherin and decreased expression of β-catenin, Slug,
and vimentin (Fig. 5c). Collectively, these results demon-
strate that NT1014 inhibits the adhesion and invasion of
ovarian cancer cells.
The effect of NT1014 on glycolytic metabolism
It is well documented that cancer cells undergo a meta-
bolic shift to adapt and survive under harsh environ-
ments by enhancing aerobic glycolysis (i.e., the Warburg
Fig. 3 NT1014 induced cell cycle G1 arrest and cellular apoptosis. The IGROV-1 and SKOV3 cell lines were treated with NT1014 for 24 h. Cell cycle
progression was analyzed by Cellometer. NT1014 induced G0/G1 cell cycle arrest and reduced S phase in a dose-dependent manner in both cell
lines (a, b). The effect of NT1014 on cell cycle-related proteins (p21, p27, cyclin D1, CDK4, and CDK6) was assessed by Western blotting (c). Both
cells were treated with varying doses of NT1014 for 24 h, and cell apoptosis was examined by an annexin V FITC assay via Cellometer. NT1014
significantly increased annexin V expression in a dose-dependent manner (d). The activity of cleaved caspase 3 was detected by ELISA assay after
treatment of NT1014 for 4 h (e). Western blotting showed that NT1014 decreased the expression of BCL-xL and Mcl-1 in the IGROV-1 and SKOV3
cell lines after exposure to NT1014 for 24 h (f). α-tubulin used as a loading control. *p < 0.05 and **p < 0.01
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effect). Cancer cells exhibit increased expression of glu-
cose transporters as a means to enhance glucose uptake,
which in turn increases the rate of glycolytic ATP pro-
duction and ultimately leads to enhanced tumor growth
[31]. In order to investigate whether NT1014 affects
glycolysis in ovarian cancer cells, the IGROV-1 and
SKOV3 cells were incubated with NT1014 in concentra-
tions up to 1000 μM for 24 h. The cellular ATP level, as
well as glucose uptake and lactate level, was assayed.
NT1014 increased glucose uptake and lactate production
in both ovarian cancer cell lines (Fig. 6a, b). Compared
to control cells, treatment with NT1014 caused a time-
dependent increase in Glut1 expression in both cell
lines, as well as a concentration-dependent increase in
IGROV-1 cells, suggesting that NT1014 stimulates
glycolytic activity (Fig. 6d). Interestingly, NT1014 treat-
ment resulted in a decrease in ATP production in the
SKOV3 cells and an increase in ATP in the IGROV-1
cells (Fig. 6c).
To validate the causal relationship between ATP levels
and glycolytic activity, we next examined the effect of
NT1014 on glycolytic pathway. The expression of pyruvate
dehydrogenase (PDH), a critical regulator of transforming
pyruvate into acetyl-CoA, and lactate dehydrogenase
(LDHA), a key enzyme of converting pyruvate into lactate,
were analyzed after incubation with NT1014 for 24 h. We
observed increased LDHA protein expression in both cell
lines after 24 h of treatment (Fig. 6e), suggesting a direct
effect of NT1014 on glucose metabolism and enhanced
activity of the glycolytic pathway in the ovarian cancer cells.
In addition, we also found that PDH expression was
elevated in the IGROV-1 cells and was decreased in the
SKOV3 cells after 24 h of treatment, suggesting that the
function of complex I in SKOV3 cells compared to
IGROV-1 cells was more profoundly influenced by
NT1014. Given that biguanides target complex I and subse-
quently increase glycolytic activity in cancer cells, the
differential metabolic reactions of NT1014 on the glycolytic
pathway and complex I suggest that ovarian cancer cells
have a different metabolic state in response to NT1014
compared to other biguanides such as metformin.
NT1014 decreased tumor growth in the KpB serous
ovarian cancer mouse model
The in vivo anti-tumor efficacy of NT1014 was evaluated in
the KpB serous ovarian cancer mouse models. The KbB
mice were divided into three groups (n = 15/group) and
were treated with NT1014 and metformin (75 mg/kg/day,
6 times/week) or placebo for 4 weeks. Tumor growth
during the treatment period was monitored using twice
weekly palpation. NT1014 or metformin was well tolerated.
The mice showed no overt signs of toxicity and maintained
normal activities throughout treatment. Twice-weekly
measurements yielded no changes in blood glucose or
Fig. 4 NT1014 induced cellular stress in ovarian cancer cells. The IGROV-1 and SKOV3 cells were treated with NT1014 and metformin at the indicated
doses for 4 h, and the ROS production was determined using the DCFH-DA assay. NT1014 increased the ROS level in a dose-dependent manner
(a, b). The expression of cellular stress proteins (PERK, Bip, and calnexin) was detected by Western blotting after treatment of NT1014 for 24 h
(c). *p < 0.05 and **p < 0.01
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mouse weight during NT1014 and metformin treatment
(data not shown). After 4 weeks of treatment, the mice
were euthanized, and the ovarian tumors were removed,
photographed, and weighed. Both NT1014 and metfor-
min resulted in significant suppression of tumor growth
relative to the control. NT1014 showed more signifi-
cant inhibition in tumor growth compared to metfor-
min at the same dose, as evidenced by a decrease in
tumor weight of approximately 70 % in NT1014 group and
46 % in metformin (p < 0.05) (Fig. 7a, b).
To further investigate the anti-tumor activity and
mechanism of NT1014 in vivo, the expression of Ki-67,
phosphorylated (phos)-AKT, phos-AMPK, phos-S6, and
MMP9 in the ovarian tumor tissues was evaluated by
IHC. Consistent with our results in vitro, the expression
of phos-AMPK and phos-AKT was induced in the mice
treated with NT1014, whereas NT1014 reduced the
levels of phos-S6 in the treated mice but not in the
untreated mice (Fig. 7d). These findings suggest that
NT1014, like other biguanides, inhibits tumor growth of
ovarian cancer in vivo via AMPK activation and inhib-
ition of the mTOR pathway. Additionally, Ki-67 and
MMP9 expression were significantly reduced following
NT1014 treatment compared to the untreated controls
(Fig. 7d). Serum VEGF levels were measured by ELISA
assay at the end of the treatment. Mean VEGF level in
treated group was significantly lower than that in control
group (Fig. 7c). These results further support the role of
NT1014 in the inhibition of tumor adhesion and inva-
sion in ovarian cancer in vivo.
Discussion
NT1014 was designed as a novel AMPK activator with
high affinity for OCT1 and OCT3. We find that NT1014
is a potent anti-tumorigenic agent that suppresses
ovarian cancer cell proliferation and in vivo ovarian
tumor growth through activation of AMPK. In addition,
our results demonstrate that NT1014 inhibits cell prolif-
eration and tumor growth with higher potency than
metformin at similar doses in both ovarian cancer cell
lines and in the KpB mouse model. Along with AMPK-
induced inhibition of mTOR signaling which has been
shown to trigger the anti-tumorigenic activities of met-
formin, NT1014 interferes with multiple AMPK-
dependent downstream signaling pathways that regulate
survival, energy metabolism, oxidative stress, and cell
migration in ovarian cancer cells.
Cell proliferation assays revealed a dose-dependent
inhibition of cell growth by NT1014 in both human
ovarian cancer cell lines tested. The drug concentrations
required to induce growth inhibition are much lower
Fig. 5 The effect of NT1014 on adhesion and invasion in ovarian cancer cells. The IGROV-1 and SKOV3 cells were cultured for 24 h and then
treated with NT1014 (1–1000 μM) in a laminin-coated 96 well plate or BME-coated 96 transwell plate for 2 or 24 h to assess adhesion and invasion
in a plate reader. The data represents relative inhibition in each cell line (a, b). The expression of E-cadherin, β-catenin, Slug, and vimentin were
analyzed by Western blotting (c). *p < 0.05 and **p < 0.01
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compared to metformin in the treatment of ovarian can-
cer cells in vitro. In addition, NT1014 treatment (75 mg/
kg) led to profound inhibition of ovarian tumor growth
in vivo and had increased efficacy compared to the same
dose of metformin (58 versus 33 %). Moreover, the data
support that NT1014 binds to OCT1 with higher affinity
than metformin, giving it the potential to more effect-
ively enter OCT1-expressing ovarian cancer cells. Recent
studies using metformin and AICAR (pharmacological
AMPK activators) have confirmed their ability to induce
apoptosis and cell cycle arrest in a variety of cancer cell
types [31, 32]. Our data showed that induction of apop-
tosis and cell cycle G1 arrest are key components of the
anti-tumorigenic effects of NT1014 in ovarian cancer
cells, as evidenced by induced expression of annexin V,
p27, and p21 as well as reduction of BCL, Mcl-1, cyclin
D1, and CDK expression. These effects may be the result
of activation of AMPK and direct inhibition of the
mTOR signaling pathway, given that NT1014 treatment
increased phosphorylation of AKT in the KpB mouse
model.
The underlying mechanism responsible for NT1014 as
well as metformin-induced growth inhibition has not been
entirely defined. Numerous studies have demonstrated
that metformin significantly inhibits cell proliferation
through activation of the AMPK pathway in ovarian
cancer cells; furthermore, long-term use of metformin has
been associated with decreased risk of ovarian cancer and
Fig. 6 The effect of NT1014 on glycolytic metabolism in ovarian cancer cells. The IGROV-1 and SKOV3 cells were incubated with NT1014 in concentrations
of up to 1000 μM for 24 h. The glucose uptake (a), lactate level (b), and cellular ATP level (c) were assayed. NT1014 increased glucose uptake and lactate
production. NT1014 treatment resulted in a decrease in ATP production in the SKOV3 cells and an increase in ATP in the IGROV-1 cells (c). The expression
of Glut1, LDHA, and PDH was measured by Western blotting after treatment with NT1014 for 24 h (d, e). *p< 0.05 and **p< 0.01
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improved outcomes in patients with or without diabetes
[12, 14, 33, 34]. Together, these findings suggest that
AMPK is an ideal target for the prevention and treatment
of ovarian cancer. Recent reports have shown that AMPK
activation by metformin is associated with increased
oxidative stress leading to upregulated cell cycle arrest
and induction of apoptosis in breast cancer and leukemia
[35, 36]. The level of oxidative stress correlated to
metformin-dependent apoptosis induction in breast
cancer [37]. A dose-dependent increase in reactive oxygen
species formation with NT1014 treatment was found in
this study. Similar NT1014 treatment at different concen-
trations resulted in an increase in expression of PERK,
Bip, and calnexin, which are markers of oxidative stress
associated with apoptosis [36]. Our data not only confirms
that NT1014 induces cell cycle arrest and apoptosis but
also demonstrates that NT1014 induces oxidative stress in
the endoplasmic reticulum of treated ovarian cancer cells.
The mechanism of apoptotic death may be triggered by
the inability of ovarian cancer cells to adequately respond
to oxidative stress in the endoplasmic reticulum.
Cell migration is a highly complex process, which
involves orchestrated dynamic remodeling of the actin
cytoskeleton and microtubule network [38]. AMPK has
been recently documented to be involved in this process
in cancer cells [38]. Pharmacological activation of AMPK
by metformin and other biguanides disturbs cancer cell
migration and invasion. Several studies have shown that
AMPK inhibits cell migration, which could occur
through different mechanisms including disruption of
the mTOR, TGF-b, Pdlim5, CXCL12, NF-kB, and
Akt-MDM2-Foxo3a pathways [38–43]. Thus, it is rea-
sonable to believe that AMPK activity affects directional
cell migration by regulating cell epithelial-mesenchymal
Fig. 7 The effect of NT1014 on ovarian tumor growth in the KpB serous ovarian cancer mouse model. Thirty KpB mice were divided into three
groups and treated with NT1014 and metformin (oral gavage, 75 mg/kg/day, 6 times/ week) or placebo for 4 weeks. The graph shows weekly
tumor volumes for each group (a) and tumor weight after treatment (b). The level of VEGF in NT1014 group was significantly lower than that in
control group (c). The changes of Ki67, phos-AKT, phos-AMPK, phos-S6, and MMP9 were assessed by immunohistochemistry in the ovarian cancer
tissues. The expression of Ki-67, phos-S6 and MMP9 was significantly reduced and phos-AKT and phos-AMPK was increased in the NT1014 treat-
ment group compared with the control group (d). *p < 0.05 and **p < 0.01
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migration. In this study, our results demonstrated that
treatment with NT1014 modifies the phenotype of
ovarian cancer cells from a mesenchymal to an epithelial
phenotype as evidenced by increased expression of the
epithelial marker E-cadherin and decreased expression
of the mesenchymal marker Slug. Thus, NT1014 may
have an improved ability to inhibit ovarian cancer
metastasis and progression through regulation of the
epithelial-mesenchymal transition.
One of the principal metabolic alternations related to
cell proliferation in tumors is the upregulation of aerobic
glycolytic metabolism [44]. Activating AMPK by differ-
ent agonists results in differential effects on glycolytic
metabolism in cancer cells [45]. Metformin is believed
to have an inhibitory effect on mitochondrial oxidative
phosphorylation via inhibiting respiratory complex I,
thus boosting glycolysis as a compensation mechanism.
The effects of NT1014 on glycolysis in ovarian cancer
cells parallel those reported for metformin in other types
of cancer [45–49]. NT1014 exposure led to an increase
in phosphorylation of AMPK and glucose uptake con-
sistent with an increase in glycolysis, characterized by in-
creased lactate production and increased levels of
LDHA. Emerging evidence has confirmed that metfor-
min effectively reduces mitochondrial ATP production
[49, 50]. In contrast, we found an increase in ATP levels
with increased PDH expression in IGROV-1 cells, but a
decrease in ATP levels and PDH expression in SKOV3
cells, after treatment of NT1014 for 24 h, despite phos-
phorylation of AMPK in both cell lines after 12 h of
treatment. These results suggest that increased ATP
production in IGROV-1 cells via increased PDH expres-
sion and acetyl-CoA represents a mechanism that par-
tially compensates for the NT1014-associated decrease
in ATP production by oxidative phosphorylation. There-
fore, NT1014 may possess an alternative mechanism to
regulate glucose metabolism and inhibit cell proliferation
compared to metformin in ovarian cancer cells.
Conclusions
In conclusion, the results from this study show that
NT1014 is a novel, orally bioavailable, and well-tolerated
AMPK activator with a high affinity for OCT1 and OCT3.
NT1014 causes significant inhibition of ovarian cancer cell
proliferation in vitro and has anti-tumorigenic activity in
vivo against ovarian cancer through modulation of multiple
signaling pathways associated with cancer cell survival, me-
tabolism, and progression. These results show promise for
the use of NT1014 as a potential anti-cancer agent for the
treatment of ovarian cancer. The efficacy of NT1014 in
other ovarian cancer cell lines and mouse models, given
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